GET DAILY SIGNALSAcme United (ACU) Delivers +18% Sales Growth in Q3 2026 with Solid Earnings Beat
Key Takeaways
- Acme United reported third quarter 2026 net sales of $58.0 million, up 18% from $49.1 million in the prior-year period.
- Net income rose 80% to $3.4 million, and diluted earnings per share (EPS) climbed 74% to $0.80, surpassing consensus estimates by $0.14.
- A $6 million tariff refund under the IEEPA (International Emergency Economic Powers Act) boosted results; excluding one-time items, adjusted EPS was $0.55, up 20%.
- Gross margin expanded to 45.3% from 39.1%, helped by the tariff refund and higher-margin direct-to-consumer sales.
- U.S. segment sales rose 20%, while Europe and Canada grew 7% and 12%, respectively, in local currency.
Putting the Quarter in Context
Acme United Corporation supplies first aid, cutting, measuring, and safety products under brands such as First Aid, Westcott, DMT, Spill Magic, and the recently acquired My Medic. The third quarter carries seasonal weight for the company, covering the key back-to-school window for its Westcott cutting tools while first aid products provide steady support. I was watching to see how the January 2026 My Medic acquisition would integrate and whether tariff effects would skew the numbers. The results gave a clearer picture of underlying demand once the one-time tariff refund and plant closure accrual were accounted for. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
Acme United reported third quarter 2026 net sales of $58.0 million, an 18% increase from $49.1 million a year earlier. Excluding the My Medic acquisition, sales still rose 10%. Net income climbed 80% to $3.4 million, and diluted EPS increased 74% to $0.80 from $0.46, beating consensus estimates by $0.14 on EPS and topping revenue forecasts by roughly $1.3 million.
The quarter included notable one-time items. The company received a $6 million tariff refund under the IEEPA (International Emergency Economic Powers Act), of which $4 million was recognized as a reduction in cost of goods sold. Offsetting this were a $1 million variable compensation expense tied to the refund and a $1.8 million accrual for closing the DMT sharpening facility in Marlborough, Massachusetts. Excluding the net one-time impact, adjusted net income was $2.4 million, up 24%, and adjusted diluted EPS was $0.55, up 20%.
Gross margin expanded to 45.3% from 39.1%, reflecting the tariff refund benefit and favorable mix from higher-margin direct-to-consumer products. Selling, general, and administrative (SG&A) expenses rose to $21.8 million, or 37.6% of sales, from $16.2 million, or 32% of sales, largely due to the My Medic integration and its associated advertising. For the first nine months of 2026, net sales reached $173 million, up 16%, with diluted EPS of $2.29 versus $2.03 a year earlier. From what I see, the underlying trends look constructive once the adjustments are stripped out.
Market Reaction and Investor Sentiment
Shares of ACU moved higher following the release, with the stock advancing in after-hours and intraday trading as investors absorbed the top-and-bottom-line beat. The headline 80% jump in net income was well received, though analysts noted that the reported figures were flattered by the one-time tariff refund. The company's commentary around a strong back-to-school season, smooth My Medic integration, and a seasonally strong fourth quarter supported a constructive tone. At the same time, management flagged rising freight costs and inflation, as well as pressure on consumer discretionary spending, which tempered some of the enthusiasm around the print.
Forward Outlook and Key Factors to Monitor
Looking ahead, management reiterated expectations for a seasonally strong fourth quarter of 2026, with My Medic historically generating the majority of its profitability in the final months of the year. The company also indicated it has already booked new first aid business and continues to see strength in its cutting tools segment, providing early momentum heading into 2027.
Several operational items are worth monitoring. The DMT plant closure is expected to generate more than $1 million in annual savings beginning January 2027, while the newly automated Spill Magic facility in Tennessee has helped drive roughly 34% year-to-date growth in that product line. The company plans to begin shipping its new SmartCompliance First Aid kit, which uses RFID (radio-frequency identification) technology to automate replenishment orders, in January 2027.
Key risk factors include elevated inventory levels built as a buffer against supply chain disruptions and rising freight costs, which management acknowledged as tripling from China. Higher shipping and raw material expenses, along with stress on consumer disposable income, could pressure margins. Investors will also be watching for potential acquisition activity, as management described the company as a consolidator in the first aid industry and signaled that additional deals are likely within the next twelve months. I’m watching this closely as the company moves into the new year.
Exploring Tickeron’s AI Daily Buy/Sell Signals
In my own research process, I frequently use Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum and timing around earnings releases like this one. The platform highlights pattern-based opportunities across a wide range of stocks and helps me quickly compare ACU against peers in the industrials space. It has become a regular part of how I evaluate whether short-term moves align with longer-term fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACU's Stochastic Oscillator sits in overbought zone for 2 days
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ACU as a result. In 82 of 112 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for ACU just turned positive on October 22, 2026. Looking at past instances where ACU's MACD turned positive, the stock continued to rise in 43 of 63 cases over the following month. The odds of a continued upward trend are 68%.
ACU moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +0.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACU advanced for three days, in 160 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ACU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.009) is normal, around the industry mean (21.114). P/E Ratio (24.739) is within average values for comparable stocks, (17.408). Projected Growth (PEG Ratio) (0.140) is also within normal values, averaging (1.518). Dividend Yield (0.010) settles around the average of (0.034) among similar stocks. P/S Ratio (1.207) is also within normal values, averaging (1.931).
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a supplier of cutting devices, measuring and safety products to the school, home, office, hardware and industrial markets
Industry HouseholdPersonalCare
Advertisement